Escitalopram - A review of its use in the management of anxiety disorders

被引:37
作者
Dhillon, Sohita [1 ]
Scott, Lesley J. [1 ]
Plosker, Greg L. [1 ]
机构
[1] Adis Int Ltd, Auckland 1311, New Zealand
关键词
D O I
10.2165/00023210-200620090-00010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Escitalopram (Cipralex (R), Lexapro (R), Seroplex (R), Sipralexa (R)), the therapeutically active S-enantiomer of racemic citalopram (RS-citalopram), is a potent and highly selective serotonin reuptake inhibitor. It is effective and generally well tolerated in the treatment of moderate to severe generalised anxiety disorder (GAD) or social anxiety disorder (SAD), panic disorder (with or without agoraphobia) as well as obsessive-compulsive disorder (OCD). Moreover, escitalopram is at least as effective as paroxetine for the treatment of GAD, SAD or OCD and appears to achieve a more rapid response than racemic citalopram in the management of panic disorder. Generally, it has a more favourable tolerability profile than paroxetine in terms of fewer discontinuation symptoms. In addition, a favourable pharmacokinetic profile permits once-daily administration of the drug. Additional comparative studies are required to definitively position escitalopram with respect to other SSRIs and venlafaxine. Nevertheless, available clinical data indicate that escitalopram is an effective first-line treatment option for the management of GAD, SAD, panic disorder and OCD.
引用
收藏
页码:763 / 790
页数:28
相关论文
共 82 条
[1]   Prevention of relapse in generalized anxiety disorder by escitalopram treatment [J].
Allgulander, Christer ;
Florea, Ioana ;
Huusom, Anna K. Trap .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 (05) :495-505
[2]   The pharmacokinetics of escitalopram in patients with hepatic impairment [J].
Areberg, J ;
Christophersen, JS ;
Poulsen, MN ;
Larsen, F ;
Molz, KH .
AAPS JOURNAL, 2006, 8 (01) :E14-E19
[3]   Escitalopram and paroxetine in the treatment of generalised anxiety disorder - Randomised, placebo-controlled, double-blind study [J].
Baldwin, David S. ;
Huusom, Anna Karina Trap ;
Maehlum, Eli .
BRITISH JOURNAL OF PSYCHIATRY, 2006, 189 :264-272
[4]   Discontinuation symptoms in depression and anxiety disorders [J].
Baldwin, David S. ;
Montgomery, Stuart A. ;
Nil, Rico ;
Lader, Malcolm .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2007, 10 (01) :73-84
[5]  
Baldwin David S, 2005, Expert Rev Neurother, V5, P443, DOI 10.1586/14737175.5.4.443
[6]   Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology [J].
Baldwin, DS ;
Anderson, IM ;
Nutt, DJ ;
Bandelow, B ;
Bond, A ;
Davidson, JRT ;
den Boer, JA ;
Fineberg, NA ;
Knapp, M ;
Scott, J ;
Wittchen, HU .
JOURNAL OF PSYCHOPHARMACOLOGY, 2005, 19 (06) :567-596
[7]  
Belzer Kenneth, 2004, J Psychiatr Pract, V10, P296, DOI 10.1097/00131746-200409000-00003
[8]   A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder [J].
Bielski, RJ ;
Ventura, D ;
Chang, CC .
JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (09) :1190-1196
[9]  
Bielski Robert J, 2005, Ann Clin Psychiatry, V17, P65, DOI 10.1080/10401230590932326
[10]   A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients [J].
Boulenger, J. -P. ;
Huusom, A. K. T. ;
Florea, I. ;
Baekdal, T. ;
Sarchiapone, M. .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (07) :1331-1341